Inclusion Criteria:
* Must have relapsed or refractory multiple myeloma (RRMM) after having received prior lines of anti-myeloma treatments, including being refractory to a proteasome inhibitor, immunomodulatory agent and an anti-CD38 monoclonal antibody
* Measurable disease as defined by one of the following: abnormal serum or M-protein levels; abnormal serum free light chain (FLC) assay; ≥ 30% clonal plasma cells in the bone marrow aspirate or biopsy sample
* Pulse oximetry ≥ 92% on room air
* Eastern Cooperative Oncology Group (ECOG) performance of 0 - 2
* Be willing and able to comply with the study schedule and all study requirements
* Willing to follow contraception guidelines
Exclusion Criteria:
* Prior systemic anti-tumor therapy or an investigational drug within 5 half-lives or 4 weeks of D1, whichever is shorter, preceding the first dose of study drug
* Prior treatment with allogeneic hematopoietic stem cell transplantation within 6 months, has active graft versus host disease following transplant or currently receiving immunosuppressive therapy following transplant
* Diagnosis of other malignancies if the malignancy required therapy in the last 3 years or is not in complete remission
* Current history of CTCAE Grade 3 muscle paresis or ocular disorders that are Grade 3 or 2
* Has any clinically significant low baseline lab results for hemoglobin, platelet counts, and neutrophil counts at screening
* Abnormal INR or aPTT, unless on a stable dose of an anticoagulant
* Has ≥ Grade 3 neuropathy or Grade 2 neuropathy with associated pain
* Has any clinically significant baseline lab results for creatinine clearance, serum aspartate aminotransferase, alanine aminotransferase, total bilirubin
* New York Heart Association Class \> 2
* Left ventricular ejection fraction \< 40%
* Prolonged QTcF interval on a 12-lead electrocardiogram
* Has active COVID-19 infection, and not present with symptoms within 4 weeks of study drug
* Has an active bacterial, viral, or fungal infection
* Has known HIV or acquired immunodeficiency syndrome-related illness, acute or history of chronic hepatitis B or C
* Is currently pregnant or breast feeding or planning on either during the study
* Has any significant medical condition, abnormality, or psychiatric illness that would prevent study participation
* Has any additional clinical history that would place the patient at an unacceptable risk if the patient participates in the study
